Tanveer Akhtar

Latest innovations in molecular biology, genetics and cell biology have revolutionized the understanding of disease parthenogenesis and efforts related to discovery of novel disease biomarkers and drug targets, eventually leading to development of more effective medication with fewer side effects. A special focus of these cutting-edge approaches has been the field of leukemia and other blood cancers with discovery of many new cancer-causing genes and therapies directly targeting cancer cells and oncogenes. Acute Myeloid Leukemia (AML) has undergone major innovations in terms of early diagnosis, molecular sub-classification of the disease, prognostic stratification and new drug discovery, culminating into patient-tailored treatment of AML patients. This books provides an account of the biology and account of genetic basis of AML and their implication in clinic and research.

21st century innovations in cutting-edge technologies have led to discovery of novel genetic, immunology and cell biological mechanisms underlying biology and parthenogenesis of diseases. A special revolution has been made by this in diagnosis, prognosis and treatment of hematological malignancies specifically leukemia. A large number of molecular genetic assays have been developed that help in selection of appropriate drugs and clinical protocols for leukemia patients, leading to patient-tailored treatment with higher clinical outcomes and fewer drug side-effects. In this era of genomic medicine, basic genetic testing had become need of every clinic and hospital. This book provides an account of classical and novel genetic abnormalities in different types of leukemia and their clinical implication. It provides standard clinically validated protocols for detection of classical genetic aberrations in leukemia. It also provides an up-to-date account of mutations associated with different types of hematological malignancies.